The subject of this publication is the conclusion of agreements pursuant to § 130a Abs.8 SGB V on the active ingredient ranolazine within the framework of a so-called open house procedure. For details, see Go.

The subject of this publication is the conclusion of agreements pursuant to § 130a Abs.8 SGB V on various active ingredients/active ingredient combinations within the framework of a so-called open house procedure. Under the specification of uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or associations of pharmaceutical companies are offered the conclusion or accession to a discount agreement according to § 130a Abs. 8 SGB V for the named active ingredient. Interested pharmaceutical companies can, after registration, download the order documents (participation documents and contract) at: https://www.dtvp.de/Satellite/notice/documents.

The procedures referred to in Section I: Contracting authorities, item 1.3.) Communication for the purpose of unrestricted and complete, toll-free access to the order documents does not exist. Information can only be obtained via your registration on the “DTVP” award platform, under the communication tab. Information and answers about other bodies are not binding.

The prerequisite for the conclusion of a contract is that the interested pharmaceutical company submits the required procedural documents completely completed and signed. Any pharmaceutical company that meets the eligibility requirements and documents this by signing the declarations and the discount agreement can join the discount agreement. An exclusivity is not given. The accession or the conclusion of the contract can take place at any time and under the same conditions. Individual contract negotiations are not carried out. The start of the contract can only be one month first. The earliest contract start is 01.02.2023. Based on this, the contract term is a maximum of 24 months. The contract ends at the latest on 31.01.2025, regardless of the date of conclusion of the contract. The offer must be submitted by 23.12.2022 at the latest at the start of the contract on 01.02.2023; however, no contracts will be concluded by AOK Nordost before 03.01.2023. For a later start of the contract, the submission deadline of the offers is the 5th of the respective previous month. (Example: contract start 01.03.2023; Deadline for submission of the offer: 05.02.2023).

Should AOK Nordost award an exclusive contract for the active ingredient within the framework of an open procedure during the term of the contract, the contractual provisions concluded in the context of this publication shall apply. This publication does not constitute a public contract within the meaning of the Public Procurement Coordination Directive 2014/24/EU of the European Parliament and of the Council or public procurement law. In order to ensure the greatest possible degree of transparency for the intended conclusions, they are published in the Supplement to the Official Journal of the European Union. In the absence of a publication form, this form of contract notice shall be used. The resulting conceptual requirements, such as the process designation open procedure, are solely due to the use of this announcement form and the publication platform. A further meaning, in particular a submission to procurement law regulations, insofar as they are not obliged for legal reasons, is not connected with it. An announcement of the awarded contracts takes place exclusively under the following link: https://www.aok.de/gp/apotheker-pharmazeutisches-personal/arzneimittelrabattvertraege/arzneimittelrabattvertraege-worum-geht-es.